[New - The 5 SVB Critical Questions And Answers For Biotech](https://wbbsec.com/opinions-and-features/)
[New - The 5 SVB Critical Questions And Answers For Biotech](https://wbbsec.com/opinions-and-features/)
powered by bulletin
In: Press Releases

For Immediate Release

December 22, 2020

CRANFORD, NJ – WBB Securities acted as co-manager for a public offering, pre-funded warrants and warrants for SCYNEXIS, Inc. on December 22, 2020. Gross proceeds to SCYNEXIS Inc. from the offering are approximately $85.0 million, before deducting the underwriting discount and estimated offering expenses.  The offering consisted of 8.3 million common shares of SCYNEXIS Inc. common stock at a price to the public of $6.25 per share.


This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.


About WBB Securities.

WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused primarily in the life sciences niche. Established in 2001 with offices in New Jersey, New York, and California. WBB Securities is registered with the SEC as a broker-dealer and is a member of the Financial Regulatory Authority, as well as a state registered investment advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high net-worth clients.


About SCYNEXIS, Inc. 

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. It is currently under review by the FDA as a treatment for vaginal yeast infections and in late-stage development for multiple life-threatening fungal infections in hospitalized patients.